Biogen Pharmachem Industries Ltd
Biogen Pharmachem Industries Ltd (BIOGEN) last reported results for the quarter ended Jun 2026, with sales of ₹0.44 crore and net profit of ₹0.22 crore. The stock last traded at ₹0.27, a market capitalisation of ₹28.4 crore. Over the past 52 weeks the stock has ranged between ₹0.25 and ₹0.77. Figures are as of 6 Oct 2026 and are not real time.
Biogen Pharmachem Industries Ltd share price and key metrics
- Current price
- ₹0.27
- Market cap
- ₹28.4 cr
- Book value
- ₹0.94
- ROE
- 0.90%
- ROCE
- 1.01%
- Dividend yield
- 0.00%
- 52w high / low
- 0.77/0.25
Metrics as of 6 Oct 2026. Not real time.
Track Biogen Pharmachem Industries Ltd
Cruxal reads every Biogen Pharmachem Industries Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Biogen Pharmachem Industries Ltd growth and returns
- 10 Years
- %
- 5 Years
- 10%
- 3 Years
- %
- TTM
- 16%
- 10 Years
- 41%
- 5 Years
- 20%
- 3 Years
- 85%
- TTM
- -114%
- 10 Years
- 2%
- 5 Years
- -12%
- 3 Years
- -27%
- 1 Year
- -63%
- 10 Years
- -1%
- 5 Years
- 1%
- 3 Years
- 1%
- Last Year
- 1%
Biogen Pharmachem Industries Ltd quarterly results
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 1.35 | 0 | 0 | 0.54 | 0.58 | 0.44 |
| Expenses | 0.35 | 0.54 | 0.17 | 0.2 | 0.39 | 0.08 | 0.94 | 0.22 |
| Operating profit | -0.35 | -0.54 | 1.18 | -0.2 | -0.39 | 0.46 | -0.36 | 0.22 |
| OPM % | — | — | 87.41% | — | — | 85.19% | -62.07% | 50.00% |
| Other income | -0.65 | 0.23 | 0 | 1.54 | -0.1 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -1 | -0.31 | 1.18 | 1.34 | -0.49 | 0.46 | -0.36 | 0.22 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net profit | -1 | -0.31 | 1.18 | 1.34 | -0.49 | 0.46 | -0.36 | 0.22 |
| EPS (₹) | -0.01 | -0.00 | 0.02 | 0.01 | -0.00 | 0.00 | -0.00 | 0.00 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Biogen Pharmachem Industries Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0.11 | 0.95 | 0 | 1.62 | 2.47 | 0 | 2.38 | 1.2 | 2.55 | 1.56 |
| Operating profit | -0.12 | -6.61 | 0 | -0.12 | -1.6 | -0.02 | -0.45 | 1.93 | -0.29 | 0.95 | -0.07 |
| OPM % | — | -6,009.09% | 0.00% | — | -98.77% | -0.81% | — | 81.09% | -24.17% | 37.25% | -4.49% |
| Net profit | -0.12 | -6.56 | 0 | -0.12 | -1.6 | -0.01 | 0.46 | 1.93 | -0.29 | 0.86 | -0.17 |
| EPS (₹) | -0.00 | -0.09 | 0.00 | -0.00 | -0.02 | -0.00 | 0.01 | 0.03 | -0.00 | 0.01 | 0.00 |
TTM is the trailing twelve months to the most recent quarter.
Biogen Pharmachem Industries Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 90.26 |
| Reserves | -4.42 | -10.98 | -10.99 | -9.51 | -11.12 | -11.13 | -10.67 | -8.74 | 26.67 | 8.83 |
| Borrowings | 0.72 | 0.01 | 0.63 | 0.31 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other liabilities | 1.69 | 1.64 | 2.73 | 0.03 | 0.11 | 0.82 | 0.24 | 0.30 | 0.09 | 0.31 |
| Total liabilities | 63.25 | 55.93 | 57.63 | 56.09 | 54.25 | 54.95 | 54.83 | 56.82 | 92.02 | 99.40 |
| Fixed assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 22.39 | 3.52 | 6.25 | 6.45 | 9.49 | 6.95 | 8.85 | 5.44 | 23.84 | 32.78 |
| Other assets | 40.86 | 52.41 | 51.38 | 49.64 | 44.76 | 48.00 | 45.98 | 51.38 | 68.18 | 66.62 |
| Total assets | 63.25 | 55.93 | 57.63 | 56.09 | 54.25 | 54.95 | 54.83 | 56.82 | 92.02 | 99.40 |
As reported by the company. Total assets equal total liabilities by construction.
Biogen Pharmachem Industries Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -0.07 | -13.65 | 0.09 | -1.21 | 3.95 | 1.40 | 1.70 | 1.94 | -1.08 | 1.57 |
| Cash from investing | 4.30 | 14.32 | -0.72 | 1.54 | -3.64 | -1.32 | -1.66 | -2.06 | -32.62 | -9.56 |
| Cash from financing | -4.31 | -0.71 | 0.62 | -0.32 | -0.31 | 0.00 | 0.00 | 0.00 | 35.70 | 6.30 |
| Net cash flow | -0.07 | -0.03 | -0.02 | 0.00 | 0.00 | 0.08 | 0.05 | -0.11 | 2.00 | -1.69 |
| Free cash flow | -0.07 | -13.65 | 0.09 | -1.21 | 3.95 | 1.40 | 1.70 | 1.94 | -1.08 | 1.57 |
| CFO / operating profit | 58% | 207% | — | 1,008% | -247% | -7,000% | -378% | 101% | 372% | 176% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Biogen Pharmachem Industries Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | -0.19% | -11.32% | 0.00% | -0.22% | -2.90% | -0.02% | -0.37% | 3.47% | -0.39% | 1.01% |
| Debtor days | — | 23,326.82 | 3,085.21 | — | 572.28 | 0.00 | — | 0.00 | 0.00 | 0.00 |
| Inventory days | — | — | 0.00 | — | 0.00 | 0.00 | — | — | — | — |
| Cash conversion cycle | — | 23,326.82 | 3,085.21 | — | 572.28 | 0.00 | — | 0.00 | 0.00 | 0.00 |
| Working capital days | — | 23,194.09 | 2,651.05 | — | 549.75 | 152.21 | — | -35.27 | 170.33 | -20.04 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Biogen Pharmachem Industries Ltd shareholding pattern
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Public | 99.99% | 100.00% | 99.99% | 100.00% | 100.00% | 100.00% | 99.99% | 100.00% |
| No. of shareholders | 2,80,600 | 3,03,780 | 3,02,362 | 2,98,703 | 2,93,327 | 2,89,987 | 2,89,155 | 2,93,626 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Biogen Pharmachem Industries Ltd corporate filings
- PFACompany Updatelow impact
- Biogen Pharmachem Industries Limited conducts AGM with high shareholder approval for key resolutionsAGM/EGMlow impact
Cruxal's analysis: Biogen Pharmachem Industries Limited held its 31st AGM on 29th September 2026 via…
Read the full analysis - PFAAGM/EGMmedium impact
- PFAInsider Trading / SASTlow impact
- Biogen Pharmachem Industries Ltd submits Annual Report for FY 2025-26 and schedules AGM for September 29, 2026Otherslow impact
Cruxal's analysis: Biogen Pharmachem Industries Ltd has filed its Annual Report for the financial year…
Read the full analysis - Biogen Pharmachem Industries Ltd announces book closure for corporate actionCorp. Actionlow impact
Cruxal's analysis: Biogen Pharmachem Industries Ltd has issued an intimation regarding book closure pursuant…
Read the full analysis - Biogen Pharmachem Industries Limited Announces 31st Annual General Meeting for September 29, 2026AGM/EGMlow impact
Cruxal's analysis: Biogen Pharmachem Industries Limited has issued a notice for its 31st Annual General…
Read the full analysis - Biogen Pharmachem Industries Ltd files statement of deviation or variation for fundsCompany Updatelow impact
Cruxal's analysis: Biogen Pharmachem Industries Ltd has submitted a disclosure under Regulation 32(1) of the…
Read the full analysis - Biogen Pharmachem Industries reports Q1 FY27 results with significant YoY revenue decline and sequential profit recoveryBoard Meetingmedium impact
Cruxal's analysis: Biogen Pharmachem Industries Limited reported a sharp decline in revenue from operations…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.